The sympathetic nervous system stimulates anti-inflammatory B cells in collagen-type II-induced arthritis by Pongratz, Georg et al.
Basic and translational research
Ann Rheum Dis 2012;71:432–439. doi:10.1136/ard.2011.153056432
Received 23 February 2011
Accepted 14 August 2011
Published Online First 
27 September 2011 
ABSTRACT
Background As previously shown, the sympathetic 
nervous system (SNS) shows proinfl ammatory activity 
during initiation of arthritis but is anti-infl ammatory in 
established collagen-induced arthritis (CIA). Interleukin 
10 (IL-10)-producing B cells suppress arthritis and are a 
potential target of the SNS because (1) B cells express 
functional β2-adrenoceptors (β2ARs) and (2) IL-10, at 
least in monocytes/macrophages, is regulated in a cAMP/
PKA/CREB-dependent manner.
Objective To test the hypothesis that anti-infl ammatory 
effects of the SNS in CIA are mediated by stimulating 
IL-10-producing anti-infl ammatory B cells. 
Methods Collagen-induced arthritis in DBA/1 mice, 
sympathectomy, adoptive B cell transfer, in vitro B cell 
culture, and assessment of B cell IL-10 production.
Results and conclusion Mice treated with B cells 
from SNS-intact mice showed less severe arthritis than 
mice treated with B cells from sympathectomised mice. 
This anti-infl ammatory action of B cells from SNS-intact 
mice correlated with increased IL-10 produced by B 
cells, which was mediated by norepinephrine (NE), in a 
β2AR, PKA-dependent manner. However, an NE-mediated 
increase in IL-10 was seen only in B cells from immunised 
but not naive mice, explaining in part the anti-
infl ammatory properties of the SNS in the late phase of 
arthritis. Finally, animals treated with B cells isolated from 
immunised mice and activated in vitro in the presence of 
a β2AR stimulus showed a decrease in arthritis severity 
in comparison with controls, an approach that might be 
used for future cellular treatment strategies.
INTRODUCTION
The depletion of CD20+ B cells as a treatment option 
for some rheumatic disorders—for example, rheu-
matoid arthritis, has raised again the proposition that 
B cells have a pathogenetic role in these disorders. 
However, depletion of all CD20+ cells is an unspe-
ciﬁ c approach and risks the occurrence of serious side 
effects such as infection. The optimal treatment for B 
cells would be speciﬁ c depletion of autoreactive B cells, 
on the one hand, and promotion of anti-inﬂ ammatory 
B cells, on the other. The mechanisms by which anti-
inﬂ ammatory B cells suppress chronic inﬂ ammation 
in arthritis are not completely understood. However, 
one hallmark of anti-arthritic regulatory B cells is their 
ability to produce interleukin 10 (IL-10).1
IL-10 is an anti-inﬂ ammatory cytokine, which 
suppresses antigen presentation by antigen-present-
ing cells, downregulates major histocompatibility 
complex II molecules and inhibits the expression of 
co-stimulatory molecules, preventing sufﬁ cient co-
stimulation of antigen-speciﬁ c T cells. Additionally, 
IL-10 directly suppresses the production of proin-
ﬂ ammatory cytokines, chemokines and matrix 
metalloproteinases in macrophages (reviewed by 
Mosser and Zhang2), which explains its anti-inﬂ am-
matory potential in arthritis. The overall effect of 
IL-10 on the whole B-cell population is stimulatory 
rather than immunosuppressive because IL-10 leads 
to prolonged survival, augments co-stimulation and 
induces class switch recombination.2 Nevertheless, 
a subpopulation of IL-10-producing B cells, so called 
CD1dhigh CD5high B10 cells,3 clearly shows anti-
 inﬂ ammatory properties in arthritis.1 4
The human and murine promoter of the IL-10 
gene contains several CREB-responsive elements.5 6 
Thus, it is not surprising that IL-10 production can 
be regulated through PKA/CREB-dependent mecha-
nisms, which have been shown in THP-1 cells and 
macrophages.5 7 Activity of PKA is increased by 
cAMP, which is generated, following the stimula-
tion of Gs protein coupled receptors, such as the 
β2-adrenoceptor (β2AR); a functional β2AR has also 
been shown to be expressed on B cells.8 9 Additionally, 
we reported in collagen type II-induced arthritis (CIA) 
that the sympathetic nervous system (SNS) with its 
main neurotransmitter norepinephrine (NE) has a role 
in regulating IL-10 in arthritis and has a profound effect 
on arthritis severity.10 Furthermore, it has been shown 
that the SNS plays a proinﬂ ammatory role in the early 
phase and an anti-inﬂ ammatory role in the late phase 
of the disease.10 11 The proinﬂ ammatory effect of the 
SNS in the early phase of the disease can be medi-
ated via increasing proinﬂ ammatory cytokines, such 
as interferon γ produced by T cells.12 Additionally, it 
has been reported that FOXP3-negative CD4+CD25+ 
T cells also contribute to the proinﬂ ammatory effect 
of the SNS in the early phase of CIA.11 However, the 
anti-inﬂ ammatory action of the SNS in the late phase 
of CIA has not yet been elucidated.
In this study, we tested the hypothesis that 
anti-inﬂ ammatory effects of the SNS in CIA are 
mediated by stimulating IL-10 producing anti-
inﬂ ammatory B cells.
MATERIAL AND METHODS
Animals, induction of arthritis and 
arthritis scoring
Male DBA/1 mice 6–8 weeks old (Elevage Janvier, 
Le Genest St Isle, France) were housed in cages and 
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fed standard laboratory chow and water ad libitum. There was 
a 12 h light––dark cycle. Experiments were conducted accord-
ing to institutional and governmental regulations for animal use 
(Government of the Oberpfalz AZ 54–2531.1-24/06).
Experimental arthritis was induced in DBA/1 mice, as previ-
ously described.10 On day 0, mice were immunised intradermally 
at the base of the tail with 100 μg of bovine type II collagen (CII; 
Chondrex, Redmond, Washington, USA) emulsiﬁ ed in an equal 
volume of complete Freund’s adjuvant (CFA; Sigma-Aldrich 
Chemie, München, Germany). A booster immunisation (100 μg 
CII in CFA) was administered on day 21 as indicated. Clinical 
scoring points were assigned to each limb to assess arthritis as 
described previously.13 A score of 0 (no swelling),1 (light swell-
ing) or 2 (strong swelling) was determined for four toes at each 
paw, four paws and ankle/wrist joints. The maximum score for 
each mouse was 48 points. Arthritis scoring was performed in a 
blinded manner, by the same technical assistant, always at the 
same time of the day (11:00–12:00).
Adoptive transfer experiments
Three groups of mice were immunised as described above (con-
trol donor mice, sympathectomised donor mice and sympath-
ectomised recipient mice, ﬁ gure 1A). On day 28, donor mice 
were killed by cervical dislocation, spleens were removed and 
immediately put into ice-cold phosphate-buffered saline (PBS). 
Splenectomy was performed in recipient mice at day 28 to 
remove the majority of the intrinsic B-cell pool. After prepar-
ing single-cell suspensions of donor splenocytes, B cells were 
isolated by magnetic bead cell sorting using mouse anti-B220 
magnetic beads (MACS MicroBeads; Miltenyi Biotec, Bergisch 
Gladbach, Germany). After isolation, >95% of the cells were 
CD19+/CD20+ B cells as assessed by ﬂ uorescence activated cell 
sorter (FACS) analysis. Donor B cells (5×106/200 μl PBS) were 
then injected into the tail vein of recipient mice (day 28 post-im-
munisation (p.i.)). One group received 200 μl PBS as treatment 
control (ﬁ gure 1A). After transfer, clinical scores were obtained 
every 2–3 days until the end of experiment (day 63). After sacri-
ﬁ cing the mice, heart blood was obtained and anti-CII antibody 
titres were determined in serum using a commercially available 
ELISA kit (MD Biosciences GmbH, Zürich, Switzerland).
Culture of splenocytes and B cells
Spleens were removed between 11:00 and 12:00. Single-cell sus-
pensions were obtained by passing spleens through a nylon mesh. 
For splenocyte cultures, 5×105 cells/200 μl were cultured in com-
plete RPMI medium (cRPMI: RPMI 1640, 25 mM HEPES, pH 7.4, 
5% fetal calf serum, 30 μM mercaptoethanol, 0.57 mM ascor-
bic acid, 100 U/ml penicillin, 100 μg/ml streptomycin (all from 
Sigma, Munich, Germany)) in 96-well plates and stimulated with 
anti-CD40 (clone: FGK 45.5, Miltenyi Biotec, Bergisch Gladbach, 
Germany, 5 μg/ml) and bovine CII (Chondrex, Redmond, 
Washington, USA, 50 μg/ml) in the presence or absence of NE (10–6 
M, Sigma) for 4–5 days. For B-cell cultures, cells were isolated 
using magnetic bead cell sorting by depleting CD43–, CD4– and 
Ter119+ cells from whole splenocyte suspensions (B-cell isola-
tion kit, Miltenyi Biotec, Germany). After isolation, >96% of the 
cells were CD19/CD20 positive B cells. Cells were resuspended in 
cRPMI containing anti-CD40 (5 μg/ml, clone: FGK 45.5, Milteyi 
Biotec, Bergisch Gladbach, Germany) and functional grade IL-4 
(1 ng/ml, eBioscience, Frankfurt, Germany) and cultured at a den-
sity of 2×106 cells/ml in 24-well plates for 4–5 days in the presence 
or absence of NE, the β2AR speciﬁ c agonist terbutaline, the pro-
tein kinase A (PKA) inhibitor H89, or the speciﬁ c β2AR antagonist 
nadolol at indicated concentrations. For experiments using H89 or 
nadolol, cells were incubated for 30 min before adding NE or terb-
utaline, respectively.
Treatment of mice with early arthritis with 
cultured B cells
Splenic B cells were obtained from immunised mice at day 21 
after immunisation and resuspended in cRPMI containing anti-
CD40/IL-4 as described above. B cells were cultured for 5 days 
in 12-well plates at of 2×106/ml in the presence or absence of 
NE, or terbutaline, or terbutaline + nadolol as indicated. After 5 
days, cells were counted, washed ﬁ ve times and resuspended in 
PBS at 2×106 live B cells/100 μl. Immunised mice beginning to 
show signs of synovitis at day 18 were treated with 2×106 B cells 
intravenously and the arthritis score was recorded thereafter.
Restimulation and assessment of IL-10 production
Restimulation of cultured cells and assessment of intracellular 
IL-10 was performed in accordance with methods published 
elsewhere.1 3 Brieﬂ y, after 4–5 days of culture cells were stimu-
lated with phorbol myristate actetate (PMA; 50 ng/ml; Sigma), 
ionomycin (500 ng/ml; Sigma) and lipopolysaccharides (LPS, 
10 μg/ml), as indicated. For IL-10 protein detection, cell-free 
supernatant was analysed using a BD OptEIA mouse IL-10 
ELISA kit (BD Bioscience, Heidelberg, Germany). For intracel-
lular FACS analysis, brefeldin A (10 μg/ml; Sigma) was added 
together with PMA and ionomycin. Cells were stained with 
ﬂ uorescein isothiocyanate-anti-mouse CD19 (clone: MB 19-1, 
eBioscience) for 15 min on ice. Then cells were ﬁ xed (2% para-
formaldehyde, 20 min at 4°C), permeabilised using Cytoﬁ x/
Cytoperm (BD-Pharmingen, Heidelberg, Germany) and stained 
with phycoerythrin-IL-10 monoclonal antibody (clone: JES5-
16E3; eBioscience) or respective isotype control for 25 min on 
ice. FACS analysis was performed on a FACS Calibur (Becton 
Dickinson Immunocytometry Systems, San Jose, California, 
USA). Data were analysed with FlowJo Software (V.7.2.4.; Tree 
Star Inc, Ashland, Oregon, USA) or WinMDI2.8 (http://facs.
scripps.edu/software.html), respectively.
Sympathectomy
Sympathectomy was performed using saporin-coupled anti-
dopamine-β-hydroxylase antibodies or saporin-coupled control 
antibodies (Advanced Targeting Systems, San Diego, California, 
USA)10 11 by intraperitoneal injection (5 μg per animal in PBS) 7 
days before immunisation. The NE content in the spleen was 
reduced by 78% at the time of immunisation, demonstrating the 
efﬁ cacy of sympathectomy.
Statistical analysis
The non-parametric Mann–Whitney test was used to compare 
two groups and analysis of variance with post hoc tests was 
used to compare multiple groups. All analyses were conducted 
using Sigma Plot for Windows (version 11; Systat software Inc.). 
p Values <0.05 were considered signiﬁ cant.
RESULTS
The SNS ameliorates CIA by promoting 
anti-infl ammatory B cells in vivo
To test the hypothesis that the SNS promotes the development 
of anti-inﬂ ammatory B cells in CIA, B cells were adoptively 
transferred as described above and as shown in ﬁ gure1A. In 
arthritic mice treated with B cells from SNS-intact mice arthritis 
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progression stopped about 14 days after treatment (ﬁ gure1B), 
whereas treatment with B cells obtained from SNS-depleted ani-
mals resulted in a short-term aggravation of the disease as com-
pared with the PBS-treated control group (ﬁ gure 1B). This result 
supports the hypothesis that the SNS promotes development 
of B cells that show anti-inﬂ ammatory properties in the CIA 
mouse model. The effect was not mediated by a change in anti-
CII antibody titres at day 63. FACS analysis also showed that 
the percentage of B cells in the spleen and in peripheral blood 
was not inﬂ uenced by sympathectomy (data not shown).
The SNS increases IL-10 produced by B cells in vivo
B cells producing IL-10 have an anti-inﬂ ammatory action in CIA, 
and the regulatory regions of the IL-10 gene contain cAMP-
 responsive elements,1 6 rendering IL-10-producing B cells a pos-
sible target for the SNS. To determine if the SNS changes the 
Figure 1 B cells obtained from sympathetic nervous system (SNS)-intact mice show regulatory potential in collagen type II-induced arthritis. (A) 
Experimental design: DBA1/J mice were depleted of the sympathetic nervous system by saporin (SAP)-conjugated anti-dopamine β-hydroxylase 
antibodies (depleted sympathetic nervous system (SNSΘ)), or treated with SAP-conjugated isotype control antibodies (SNS⊕) 7 days before 
immunisation with bovine collagen type II in complete Freund’s adjuvant. On day 28, splenectomy was performed, B cells were isolated and SNSΘ 
arthritic mice were treated with B cells from either SNSΘ, or SNS⊕ donors, respectively. One group was treated with phosphate-buffered saline 
(PBS) only. (B) Transfer of SNS⊕ B cells stops progression of collagen-induced arthritis. Arthritis score was determined by a blinded observer during 
the indicated time period post-immunisation (days p.i.). A general linear statistical model (two-way analysis of variance with Holm–Sidak post hoc 
analysis) showed between-group differences for mice treated with SNS⊕ B cells versus mice treated with PBS (p=0.008) and mice treated with 
SNSΘ B cells (p<0.001), respectively. No signifi cant group difference was found between mice treated with PBS and mice treated with SNSΘ B cells 
(p=0.09). The average score of two independent experiments (% Ctrl) is shown. n = total number of mice. Error bars represent the SEM. (C) Serum 
level of anti-collagen type II antibodies (anti-CII) at the last day of the experiment as determined by ELISA.
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ability of B cells to produce IL-10 in vivo, splenic B cells obtained 
from immunised and non-immunised mice at day 19 p.i. from 
SNS-depleted and SNS-intact mice were compared (ﬁ gure 2A). 
B cells obtained from SNS-depleted mice produced signiﬁ cantly 
less IL-10 than the same number of B cells from SNS-intact mice 
(ﬁ gure 2B). When B cells were isolated from non-immunised 
animals sympathectomy did not inﬂ uence the amount of IL-10 
produced (data not shown). These result suggest that one func-
tion of the SNS in vivo is to promote IL-10-producing B cells 
during activation after immunisation with CII and CFA.
Norepinephrine differentially regulates IL-10 
produced by B cells from naive or 
antigen-experienced spleens
Owing to earlier ﬁ ndings that the SNS shows proinﬂ ammatory 
properties during the early phase and anti-inﬂ ammatory properties 
during the late phases of CIA,10 it was determined if NE, the main 
SNS neurotransmitter, differentially regulates IL-10 produced by 
cultured naïve splenocytes as compared with splenocytes obtained 
from antigen-experienced mice. Antigen-experienced splenocytes 
cultured for 4–5 days in the presence of anti-CD40, CII and NE 
showed increased IL-10 production after restimulation with PMA, 
ionomycin and LPS, as compared with cells in the absence of NE 
(ﬁ gure 3A). FACS analysis showed that an increase in intracellular 
IL-10 in lymphocytes was mainly seen in CD19+ B cells (ﬁ gure 
3B). However, this NE-induced increase in IL-10 was not seen 
when naïve-splenocytes were used in a similar experiment (ﬁ gure 
3C), indicating that immunisation before stimulation with NE ren-
ders some IL-10-producing, antigen-experienced splenocytes—for 
example, B cells, responsive to this neurotransmitter.
Norepinephrine acts directly on B cells to increase IL-10 
production
To determine whether the increase in IL-10-producing B cells, 
after activation of splenocytes in the presence of NE is depen-
dent on cells other than B cells in the culture, we isolated B cells 
from naive and antigen-experienced spleens and activated them 
with anti-CD40 and IL-4 in the absence (Ctrl) or presence of 
NE for 5 days and analysed IL-10+/CD19+ cells by FACS (ﬁ gure 
4A). The results are expressed as a percentage of control (% Ctrl, 
anti-CD40/IL-4 only). The absolute values for the percentage of 
IL-10+/CD19+ B cells from naïve mice (3.1% × 1.2) and antigen-
experienced mice (2.6% × 1.3) were not signiﬁ cantly different 
(p=0.953). As shown in ﬁ gure 4A, NE in a concentration-depen-
dent manner increases IL-10+/CD19+ B cells when isolated from 
spleens of mice immunised with CII/CFA (day p.i. 35–65). The 
increase was signiﬁ cant at concentrations of 10–8 to 10–6 mol/l 
(ﬁ gure 4A, solid circles). However, when B cells from naive mice 
were used, the population of IL-10+ B cells did not change in the 
presence of NE (ﬁ gure 4A, open circles). These results show that 
NE directly acts on B cells to increase IL-10+ cells, but only when 
the cells were taken from antigen-experienced spleens.
Norepinephrine increases IL-10 produced by 
B cells in a β2AR/PKA-dependent manner
Since it is known that B cells express functional β2AR, we next 
determined if speciﬁ c stimulation of this receptor with terbuta-
line could mimic the effect of NE. Terbutaline increased IL-10 
protein produced by B cells (isolated at day 35–40 p.i.) in a 
concentration-dependent manner (ﬁ gure 4B). Additionally, the 
use of a speciﬁ c PKA inhibitor, H89, showed that the terbuta-
line-induced increase in IL-10 was mediated through a PKA-
dependent pathway (ﬁ gure 4C). The addition of H89 prevented 
the increase of IL-10, and also reversed the terbutaline effect, 
resulting in decreased IL-10 production. This result suggests 
a second signalling pathway downstream of the β2AR, which 
leads to a decrease in IL-10 production upon stimulation of the 
receptor. Taken together, these results suggest that the increase 
Figure 2 Interleukin (IL)-10 produced by splenic B cells is increased 
via the sympathetic nervous system in vivo following immunisation. 
(A) Experimental design. DBA/1J mice were treated with saporin-
coupled anti-β hydroxylase antibodies (n=6) or saporin-coupled isotype 
control antibodies (n=6) 7 days before immunisation with bovine 
collagen type II in complete Freund’s adjuvant (CFA, day 0). (B) At 
day 19, 5×106 splenic B cells were stimulated with phorbol myristate 
actetate (50 ng/ml) and ionomycin (500 ng/ml) for 20 h and IL-10 was 
determined in cell-free supernatants by ELISA. p Value was determined 
by Mann–Whitney test. Results are presented as box plots, horizontal 
lines represent the median value. SNS, sympathetic nervous system.
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in IL-10 produced by anti-CD40/IL-4-activated B cells isolated 
from antigen-experienced spleens is mediated via the β2AR in a 
PKA-dependent manner.
Treatment of CIA with β2AR-stimulated 
B cells isolated from antigen-experienced mice 
ameliorates disease progression
To show that the increase in IL-10+ B cells after β2AR stimula-
tion of B cells from antigen-experienced mice in vitro is of rel-
evance in vivo, arthritic mice were treated with B cells activated 
in the absence or presence of NE, terbutaline, or terbutaline + 
nadolol, respectively (ﬁ gure 5A). Mice treated with anti-CD40/
IL-4-activated B cells (B-cell control) or PBS, respectively, showed 
the expected increase of arthritis severity over time (ﬁ gure 5B). 
There was a trend towards a faster increase of arthritis scores 
in the B-cell control group as compared with PBS control in the 
ﬁ rst 10 days after treatment (p = 0.074), but no overall signiﬁ cant 
difference (p=0.099). On the other hand, mice receiving B cells 
activated in the presence of either terbutaline or NE showed sig-
niﬁ cantly reduced arthritis severity as compared with controls 
Figure 3 Norepinephrine differentially regulates interleukin (IL)-10 produced by antigen experienced or naïve splenocytes, respectively. Splenocytes from 
mice immunised with collagen type II and complete Freund’s adjuvant (A, >day 60 post-immunisation) or naïve spleen cells from DBA1/J mice (C) were 
activated with anti-CD40 and bovine collagen type II in the presence (+NE) or absence (–NE) of norepinephrine (10-6 M). After 4–5 days, cells were washed 
and stimulated with phorbol myristate actetate, ionomycin and lipopolysaccharide, and IL-10 protein concentration was determined by ELISA at indicated 
time points. ***p<0.001 was determined by Mann–Whitney U test. n.s., not signifi cant. Results of four independent experiments with four replicates each 
are shown. (B) Representative FACS analysis of stimulated splenocytes after culture in the absence (Ctrl) or presence (+NE) of norepinephrine 10–6 M. 
Analysis of expression of intracellular IL-10 and CD19 as indicated. The number in the rectangular region indicates the percentage of IL10+/CD19+ cells.
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(ﬁ gure 5). Additionally, mice treated with B cells activated in the 
presence of terbutaline and nadolol did not differ as compared 
with the control groups (p=0.074). Taken together the results 
suggest that a β2AR stimulus during activation of B cells from 
antigen-experienced mice in vitro increases the anti-inﬂ amma-
tory activity of these cells in vivo, by increasing IL-10+ B cells.
Figure 4 Norepinephrine increases interleukin (IL)-10-producing splenic B cells via stimulation of β2-adrendergic receptors in a concentration-
dependent and protein kinase A-dependent manner. Splenic B cells from antigen-experienced mice (A, solid circles) and naïve mice (A, open 
circles) were cultured with anti-CD40 and IL-4 in the absence or presence of norepinephrine (A) or terbutaline (B) at indicated concentrations. 
(C) Terbutaline (Terb) was used at 10–6 M, H89 at 1 µg/ml. After 4–5 days of culture, B cells were stimulated with phorbol myristate actetate, 
ionomycin and lipopolysaccharide in the presence (A) or absence (B, C) of breveldin A for 8–10 h. The percentage of IL10+/CD19+ B cells 
or IL-10 protein concentration was determined by FACS analysis (A) or ELISA (B, C), respectively. Mean values expressed as percentage of 
control (anti-CD40/IL-4 only, % Ctrl) of six independent experiments (A, closed circles) and eight independent experiments (A, open circles) 
are shown. (B, C) Mean values for three independent experiments (B) and two independent experiments (C) are shown. p Values were 
determined by analysis of variance with Holm–Sidak (A, C) and Bonferroni (B) post hoc tests, respectively. Error bars represent the SEM. 
***p<0.001; **p<0.01.
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DISCUSSION
Recent studies using the CIA model system show, that the SNS 
has a dual role with respect to disease severity, with proinﬂ am-
matory activity in the early phase and an anti-inﬂ ammatory 
inﬂ uence in the late phase of arthritis.10 11 Our results in this 
study suggest that the anti-inﬂ ammatory activity of the SNS in 
the late phase of arthritis is, at least in part, mediated by increas-
ing the anti-inﬂ ammatory properties of B cells. We propose 
Figure 5 Treatment of collagen-induced arthritis with B cells activated in vitro in the presence of a β2-adrenoceptor (β2AR) agonist ameliorates 
disease progression. (A) Experimental design: fi ve mice were immunised with bovine collagen type II (CII) and complete Freund’s adjuvant (CFA). 
At day 21 post immunisation (p.i.) naïve splenic B cells were isolated and activated for 5 days with anti-CD40/interleukin (IL)-4 in the presence or 
absence of norepinephrine (10–6 M), terbutaline (10–6 M), or terbutaline (10–6 M) + nadolol (10–5 M). B cells were then vigorously washed and 
resuspended in phosphate-buffered saline (PBS). Six mice with collagen-induced arthritis per group (anti-CD40/IL-40, + norepinephrine, + terbutaline, 
+ terbutaline+nadolol) were injected intravenously with 2×106 B cells per mouse or with PBS only at day 18 p.i. (B) Transfer of β2AR-treated B cells 
signifi cantly slowed arthritis progression. Arthritis score was determined by a blinded observer during the indicated time period post immunisation 
(days p.i.). A general linear statistical model (two-way analysis of variance with Student–Newman–Keuls post hoc analysis) showed between-group 
differences for mice treated with B cells activated in the presence of norepinephrine or terbutaline, respectively, as compared with mice treated 
with PBS, or B cells activated with anti-CD40/IL-4 only, or B cells activated in the presence of nadolol + terbutaline (p<0.001 for all comparisons). 
No signifi cant group difference was found between mice treated with PBS and mice treated with B cells activated in the presence of nadolol + 
terbutaline or B cells activated with anti-CD40/IL-4 only. Symbols represent the group means, the error bars represent the SEM.
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that in the late phase of CIA a sympathetic stimulus increases 
the percentage of IL-10-producing, anti-inﬂ ammatory B cells, 
which can slow down arthritis progression.1 Our results do 
not exclude the possibility that the SNS also inﬂ uences other 
cells—for example, monocytes/macrophages, which have been 
shown to increase IL-10 production after stimulation of β2AR in 
the human system.5 7 14 However, transferring splenic B cells in 
vitro, activated in the presence of a β2AR stimulus, is sufﬁ cient 
to signiﬁ cantly slow arthritis progression, showing the impor-
tant role of the SNS and B cells, respectively, in modulating dis-
ease severity in arthritis.
A necessary prerequisite for the SNS to increase IL-10-producing 
B cells was prior immunisation with CII and CFA, which under-
lines the importance of this mechanism after initiation of arthri-
tis (late phase). The need for prior immunisation indicates that a 
proinﬂ ammatory milieu in the spleen is important to render naive 
B cells responsive for a β2AR-induced increase in IL-10. The reason 
for this is unclear. However, one possibility might be an increase 
in β2AR signalling capacity by decreasing G-protein-coupled 
receptor kinase (GRK)-2, which was reported to be decreased in 
peripheral blood mononuclear cells from patients with rheuma-
toid arthritis and upon antigen exposure in B and T cells in a rat 
model of adjuvant arthritis.15 16 This leads to the hypothesis that 
an immune challenge decreases GRK-2 in naïve B cells, resulting 
in less β2AR phosphorylation, which slows internalisation and 
desensitisation of β2ARs. This results in increased and prolonged 
β2AR signalling, which might cross a certain threshold to initiate 
PKA-dependent IL-10 production in B cells.
The importance of IL-10 in modulating arthritis severity is 
underlined by several correlative studies showing a link between 
genetic variation at the IL-10 gene locus and severity of arthri-
tis,17 18 but human studies treating arthritis with systemic 
IL-10 showed almost no effect (reviewed by Asadullah et al19). 
However, a small number of antigen-speciﬁ c T cells transfected 
to produce IL-10 were capable of suppressing inﬂ ammation in 
proteoglycan-induced arthritis,20 probably by cell–cell interaction 
at the site of inﬂ ammation without an increase in systemic IL-10. 
This ﬁ ts together with our results, which show no change in 
IL-10 serum levels upon transfer of β2AR-stimulated B cells (data 
not shown). It was not in the scope of this study to delineate, 
whether local suppressive effects occur in the joints, the lymph 
nodes, or the spleen. However, in adoptive transfer experiments, 
recipient animals were splenectomised before transfer of B cells, 
which indicates that homing to the spleen is not necessary for the 
suppressive effect of B cells from SNS-intact animals.
As mentioned in the introduction, one problem with B-cell 
depleting strategies in rheumatic disease is the unselective 
approach, which depletes both, proinﬂ ammatory and anti-
inﬂ ammatory B cells. In light of our results, it might be possible 
to enrich anti-arthritic B cells in vitro using β2-adrenergic stimuli. 
Combining this approach with B-cell depletion and retransfer of 
in vitro generated anti-arthritic B cells might open new thera-
peutic possibilities for the future.
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